Targeted therapies such as trastuzumab and the antibody-drug-conjugate T-DM1, have revolutionized the treatment for HER2+ breast cancer patients. These antibodies target HER2, the highly glycosylated driver of these cancers. Despite the knowledge on the role of glycosylation in different aspects of tumor progression, the influence of altered glycosylation on the efficacy of HER2-targeted therapies remains unknown. This proof of concept project aims to explore the impact of altered glycosylation on the response to HER2-targeted therapies and, holds the potential to open new research lines towards a deeper understanding of the molecular mechanisms underlying the response to targeted therapies in cancer.
Source: NWO
